Insensitivity of visual assessment of hippocampal atrophy in familial Alzheimer’s disease

Medial temporal atrophy is a well-established marker for Alzheimer’s disease (AD). However, due to normal variation in the size of medial temporal structures and variability in how radiologists interpret images, the use of clinical reads in establishing the presence of pathological atrophy is imprecise. A limitation of studies of magnetic resonance imaging (MRI) measures in AD is diagnostic uncertainty as it can be unknown if pre- or early-symptomatic subjects go on to develop AD and most subjects do not undergo autopsy verification of the diagnosis. In persons with or at-risk for AD due to fully-penetrant autosomal dominant mutations in the PSEN1 and APP genes, the diagnosis or future development of AD can be predicted with essentially 100% accuracy. We used this predictability to assess the ability of radiologists to detect hippocampal atrophy (HA) in persons destined to develop AD. Coronal T1-weighted MRI scans of 39 persons demented from (n = 4) or at-risk for inheriting (n = 35) PSEN1 or APP mutations were independently assessed by two radiologists and the presence or absence of HA determined. Of the 39 subjects, 26 were FAD mutation carriers. Fifteen of 28 asymptomatic at-risk persons were FAD mutation carriers and four of these were rated as having atrophy for a sensitivity of 27% and a specificity of 85%. Among seven mildly affected yet non-demented subjects, atrophy was detected in three and in the four demented subjects HA was identified in two. Our results suggest that radiologists’ ability to detect HA in persons in whom the diagnosis of incipient AD is certain is sub-optimal and quantitative MRI techniques or other biological markers of the disease are needed.

[1]  Kiralee M. Hayashi,et al.  The topography of grey matter involvement in early and late onset Alzheimer's disease. , 2007, Brain : a journal of neurology.

[2]  M. Tusié-Luna,et al.  Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer’s disease in Mexican families , 2006, Neurogenetics.

[3]  Nick C Fox,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease , 2007, Neurology.

[4]  J. Cummings,et al.  Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease. , 2009, Current Alzheimer research.

[5]  Philip Scheltens,et al.  Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment , 2004, Neurology.

[6]  J. Cummings,et al.  The A431E mutation in PSEN1 causing Familial Alzheimer’s Disease originating in Jalisco State, Mexico: an additional fifteen families , 2006, Neurogenetics.

[7]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[8]  Toru Shimizu,et al.  Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val→Ile mutation in the amyloid precursor protein gene , 1993, Neurobiology of Aging.

[9]  O Nalcioglu,et al.  Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease , 1991, Neurology.

[10]  J. H. Lee,et al.  A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. , 2001, JAMA.

[11]  P. Scheltens,et al.  Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability , 1995, Journal of Neurology.

[12]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[13]  Nick C Fox,et al.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.

[14]  R. Petersen Mild cognitive impairment as a diagnostic entity , 2004, Journal of internal medicine.

[15]  Linda Teri,et al.  Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series , 1999, Journal of the American Geriatrics Society.

[16]  Nick C Fox,et al.  Early onset familial Alzheimer’s disease , 2002, Neurology.

[17]  J. Morris,et al.  Clinical Dementia Rating: A Reliable and Valid Diagnostic and Staging Measure for Dementia of the Alzheimer Type , 1997, International Psychogeriatrics.